Activin and Inhibin

JNJ-18038683 is a 5-Hydroxytryptamine Type 7 ( 5-HT 7 ) receptor antagonist, with pK i s of 8.19, 8.20 for rat and human 5-HT 7 in HEK293 cells, respectively.In VitroJNJ-18038683 displaced, with high affinity, specific [ 3 H]5-CT binding sites from

JNJ-18038683 is a 5-Hydroxytryptamine Type 7 ( 5-HT 7 ) receptor antagonist, with pK i s of 8.19, 8.20 for rat and human 5-HT 7 in HEK293 cells, respectively.In VitroJNJ-18038683 displaced, with high affinity, specific [ 3 H]5-CT binding sites from

JNJ-18038683 is a 5-Hydroxytryptamine Type 7 ( 5-HT 7 ) receptor antagonist, with pK i s of 8.19, 8.20 for rat and human 5-HT 7 in HEK293 cells, respectively.In VitroJNJ-18038683 displaced, with high affinity, specific [ 3 H]5-CT binding sites from

JNJ-18038683 is a 5-Hydroxytryptamine Type 7 ( 5-HT 7 ) receptor antagonist, with pK i s of 8.19, 8.20 for rat and human 5-HT 7 in HEK293 cells, respectively.In VitroJNJ-18038683 displaced, with high affinity, specific [ 3 H]5-CT binding sites from

JNJ-37822681 dihydrochloride is a potent, specific, centrally active, fast-dissociating dopamine D 2 receptor antagonist with a moderate binding affinity for the dopamine D 2L receptor ( K i =158 nM), which has potential for the treatment of

JNJ-37822681 dihydrochloride is a potent, specific, centrally active, fast-dissociating dopamine D 2 receptor antagonist with a moderate binding affinity for the dopamine D 2L receptor ( K i =158 nM), which has potential for the treatment of

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD : inhibits PHD1, PHD2, and PHD3 with pK i values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.In VitroJNJ-42041935 is the most potent inhibitor of PHD2

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD : inhibits PHD1, PHD2, and PHD3 with pK i values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.In VitroJNJ-42041935 is the most potent inhibitor of PHD2

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD : inhibits PHD1, PHD2, and PHD3 with pK i values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.In VitroJNJ-42041935 is the most potent inhibitor of PHD2

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD : inhibits PHD1, PHD2, and PHD3 with pK i values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.In VitroJNJ-42041935 is the most potent inhibitor of PHD2

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD : inhibits PHD1, PHD2, and PHD3 with pK i values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.In VitroJNJ-42041935 is the most potent inhibitor of PHD2

JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy